ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Hazem El-Osta, Abdulrahman Abdulbaki, Prakash Peddi, Amol Takalkar, James Cotelingam, Diana Veillon, Andres Vargas, Nuri Akkus, Gerhard C. Hildebrandt
Lactic acidosis is a rare complication of malignancies and is seen more frequently in high grade lymphoma and leukemia. Although, its pathogenesis is not well understood, it remains a surrogate of poor prognosis. Herein, we present a case of Burkitt-like lymp…
Felicity W. K. Harper, Elisabeth I. Heath, Marci E. J. Gleason, Louis Penner, Patricia LoRusso, Ding Wang, Terrance L. Albrecht
For cancer patients on Phase I trials, one of the most important physician decisions is whether or not patients are deriving benefit from therapy. With an increasing number of cytostatic treatment agents, the criteria to determine patient response to Phase I…
Emma B. Holliday, Gregory P. Swanson, Fei Du, Joseph W. Basler
There is significant controversy on how aggressively to treat older men with prostate cancer. We identified 1082 patients diagnosed with prostate cancer from 1998-2008 with Gleason score ≥ 7 on biopsy or prostatectomy pathology in the South Texas Veteran’s He…
Anren Song, Jean Wu, Emily Whitaker, Nadarajah Vigneswaran
Head and neck squamous cell carcinoma (HNSCC) is a common tumor worldwide that often presents at an advanced stage with poor prognosis. Advanced HNSCC frequently exhibits resistance to chemotherapy limiting its efficacy. Gemcitabine is a pyrimidine-based anal…
Anna Swanson, Eleanor Cheadle, David Gilham, Dorothy Crawford, Simon Talbot, Ingo Johannessen
T cells engineered to express chimeric antigen receptors (CARs) combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) signaling domain for triggering cell activation are being used for immunotherapeutic targeting of tumor cells in…
Miao Zhang, Min Zhang, Lihua Wang, Jiajia Hu, Biao Li
Objective: To evaluate the role of PET/CT with contrast enhanced CT in diagnosing and staging for pancreatic diseases and optimize the use of enhanced PET/CT as one-stop imaging modality. Methods: Fifty-six patients who presented with suspected pancreatic car…
Patrice Cagle, Ombeni Idassi, Janelle Carpenter, Radiah Minor, Ipek Goktepe, Patrick Martin
Rosehips are blossoms from the wild rose ( Rosa canina ) and are commonly used as an herbal remedy. Previous reports have shown that extracts made from rosehip plants are able to reduce cell proliferation of cancer cells. In this study, we investigated the ef…
Michiyo Ando, Hiromi Minota, Chika Shibukawa, Haruko Kira
Objective : The aims of the study were to develop a Simple Life Review Interview as psychotherapy for terminally ill cancer patients with slight cognitive impairment, and to examine the feasibility and effects of this approach on spiritual well-being and qual…
Hiroko Yokoyama, Miyabi Ebara, Fuyuki Nakamura, Aina Nanasawa, Sachiko Tanaka, Kenji Onda, Kentaro Sugiyama, Kazuhiko Kasuya, Gulimire Muhetaer, Motohide Shimazu, Toshihiko Hirano
N -aspartylchlorin e6 (talaporfin) concentrations in cancer cells, mouse liver tissues, and human plasma specimens were determined with fluorescence microtiter plate analysis. Talaporfin standard curves were obtained in each of the sample specimens of cells,…
Sebastián Méndez-Álvarez, Gerardo Pulido-Reyes, Javier Donate-Correa, Arturo Soriano Benítez de Lugo
The appearing of microbial lineages carrying multiple dangerous loci are results from the extensive use of antibiotics and has brought a huge increase in the infections-derived morbidity and mortality, which is critical in the hospital setting. Etiologic agen…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).